The analysis, which evaluated patients with early-stage breast cancer, suggests that correcting vitamin D levels before treatment might help prevent peripheral neuropathy.
Subcutaneous efgartigimod PH20 SC is effective and tolerable for the treatment of CIDP, providing a convenient alternative to intravenous and other older treatments.